Extended Data Fig. 10: Validation of the survival impact of PPP2R1A mutations in a uterine cancer cohort receiving combined len-pem treatment.
From: PPP2R1A mutations portend improved survival after cancer immunotherapy
a-b. Kaplan-Meier survival analysis of the impact of PPP2R1A mutation status on the OS (a) and PFS (b) of uterine cancer patients with high-risk histology who received combined len-pem therapies. c-d. Kaplan-Meier survival analysis of the impact of PPP2R1A mutation status on the OS (c) and PFS (d) of uterine cancer patients with TP53 mutations who received combined len-pem therapies. e-h. Same as a-d, but for uterine cancer patients in the same cohort with WT ARID1A. For panels a-h, P values were calculated using two-sided log-rank test.
